tributyrin for Parkinson's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Parkinson's Diseasetributyrin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a potential new therapy for Parkinson's disease, called tributyrin, is safe and effective.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: after approximately 30 days of intervention

Day 30
FDG glucose PET brain
MoCa
PET metabolism
Brain
glucose metabolism
resting state fMRI

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Tributyrin Intervention
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: tributyrin · No Placebo Group · Phase 1

Tributyrin Intervention
Drug
Experimental Group · 1 Intervention: tributyrin · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tributyrin
1995
Completed Phase 1
~30

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: after approximately 30 days of intervention

Who is running the clinical trial?

Nicolaas Bohnen, MD, PhDLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
Nicolaas I Bohnen, MD, PhDPrincipal InvestigatorUniversity of Michigan
2 Previous Clinical Trials
70 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have Parkinson's disease.